前列腺癌
抗雄激素
癌症研究
医学
前列腺
癌细胞
内科学
体内
癌症
GPX4
肿瘤科
氧化应激
谷胱甘肽过氧化物酶
生物
超氧化物歧化酶
抗雄激素
生物技术
作者
Ali Ghoochani,En‐Chi Hsu,Merve Aslan,Meghan A. Rice,Holly M. Nguyen,James D. Brooks,Eva Corey,Ramasamy Paulmurugan,Tanya Stoyanova
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-01-22
卷期号:81 (6): 1583-1594
被引量:137
标识
DOI:10.1158/0008-5472.can-20-3477
摘要
Abstract Ferroptosis is a type of programmed cell death induced by the accumulation of lipid peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated that cancer cells are vulnerable to ferroptosis inducers (FIN). However, the therapeutic potential of FINs in prostate cancer in preclinical settings has not been explored. In this study, we demonstrate that mediators of ferroptosis, solute carrier family 7 member 11, SLC3A2, and glutathione peroxidase, are expressed in treatment-resistant prostate cancer. We further demonstrate that treatment-resistant prostate cancer cells are sensitive to two FINs, erastin and RSL3. Treatment with erastin and RSL3 led to a significant decrease in prostate cancer cell growth and migration in vitro and significantly delayed the tumor growth of treatment-resistant prostate cancer in vivo, with no measurable side effects. Combination of erastin or RSL3 with standard-of-care second-generation antiandrogens for advanced prostate cancer halted prostate cancer cell growth and migration in vitro and tumor growth in vivo. These results demonstrate the potential of erastin or RSL3 independently and in combination with standard-of-care second-generation antiandrogens as novel therapeutic strategies for advanced prostate cancer. Significance: These findings reveal that induction of ferroptosis is a new therapeutic strategy for advanced prostate cancer as a monotherapy and in combination with second-generation antiandrogens.
科研通智能强力驱动
Strongly Powered by AbleSci AI